Professor of Hematology and Oncology, Mayo Medical School
Hematology
Dr. Ayalew Tefferi, MD
|
|
Give Review
Ayalew Tefferi, MD practices Hematology. He has 2 awards "America's Top Doctors" and "America's Top Doctors for Cancer". Doctor Ayalew Tefferi, MD has written publications. He has 78 publications published with PubMed. The lastest paper is: 'Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Next generation sequencing of Myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation.
- Targeted next generation sequencing of PDGFRB rearranged Myeloid neoplasms with monocytosis.
- Chronic neutrophilic Leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management.
- Splenomegaly and Thrombosis risk in Essential Thrombocythemia: the Mayo Clinic Experience.
- Calreticulin (CALR) variant stratified driver mutational status and prognosis in essential thrombocythemia.
- Targeting megakaryocytic-induced fibrosis in Myeloproliferative neoplasms by AURKA inhibition.
- Indication and management of allogeneic stem Cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
- Myeloproliferative Neoplasms: A Decade of Discoveries and Treatment Advances.
- Chronic neutrophilic Leukemia: novel mutations and their impact on clinical practice.
- Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
- Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic Mast cells.
- Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.
- A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.
- Is there a role for JAK inhibitors in BCR-ABL1-negative Myeloproliferative neoplasms other than myelofibrosis?
- The rate of transformation from JAK mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.
- Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.
- Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.
- Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
- Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic Leukemia: A Mayo Clinic-French Consortium Study.
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
- Mutations and Thrombosis in essential thrombocythemia: prognostic interaction with age and Thrombosis history.
- Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.
- Calreticulin mutations and long-term survival in essential thrombocythemia.
- Chronic neutrophilic Leukemia 2014: Update on diagnosis, molecular genetics, and management.
- CALR mutation studies in chronic neutrophilic Leukemia.
- Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients.
- Genetics: CALR mutations and a new diagnostic algorithm for MPN.
- Use of the Functional Assessment of Cancer Therapy-Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia.
- Altered expression of tumor suppressor PHF20 in Myeloproliferative neoplasms.
- Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
- Drug-drug interaction between bosutinib and warfarin.
- CALR mutations are infrequent in WHO-defined refractory Anemia with ring sideroblasts.
- Chronic neutrophilic Leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment...
- Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review.
- Rethinking the diagnostic criteria of Polycythemia vera.
- The molecular genetics of Chronic neutrophilic leukaemia: defining a new era in diagnosis and therapy.
- Chronic myelomonocytic Leukemia: 2013 update on diagnosis, risk stratification, and management.
- U2AF1 mutations in primary myelofibrosis are strongly associated with Anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype.
- Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic Leukemia.
- Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing.
- Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary Myelodysplastic syndromes.
- Clonal Mast cell disease not meeting WHO criteria for diagnosis of Mastocytosis: clinicopathologic features and comparison with indolent Mastocytosis.
- Mayo prognostic model for WHO-defined chronic myelomonocytic Leukemia: ASXL1 and spliceosome component mutations and outcomes.
- Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
- Nilotinib treatment-associated cerebrovascular disease and stroke.
- Survival and prognosis among 1545 patients with contemporary Polycythemia vera: an international study.
- AKT is a therapeutic target in Myeloproliferative neoplasms.
- Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia Vera ...
- Personalized management of essential thrombocythemia?application of recent evidence to clinical practice.
- SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic Leukemia (CMML): independent prognostic impact in CMML.
- Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
- CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic Leukemia.
- Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.
- Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
- Prognostic impact of RAS mutations in patients with Myelodysplastic syndrome.
- International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response crite...
- Increased circulating IL-2R? (CD25) predicts poor outcome in both indolent and aggressive forms of Mastocytosis: a comprehensive cytokine-phenotype study.
- Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic Leukemia: Prevalence, clinical correlates, and prognostic relevance.
- Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system amo...
- Lymphoma-associated versus lymphocytic-variant hypereosinophilia.
- Treatment-refractory idiopathic hypereosinophilic syndrome: Pitfalls and progress with use of novel drugs.
- Sole abnormalities of chromosome 7 in Myeloid malignancies: Spectrum, histopathologic correlates, and prognostic implications.
- Plasma cytokines in Polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis.
- Chronic myelomonocytic Leukemia: 2012 update on diagnosis, risk stratification, and management.
- Why does my patient have Thrombocytosis?
- Myeloproliferative neoplasms cause glomerulopathy.
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using Cell lines and primary Cells from polycythemia vera pa...
- The complete evaluation of erythrocytosis: congenital and acquired.
- Frequent TET2 mutations in systemic Mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.
- TET2 mutations and their clinical correlates in Polycythemia vera, essential thrombocythemia and myelofibrosis.
- Rationale for revision and proposed changes of the WHO diagnostic criteria for Polycythemia vera, essential thrombocythemia and primary myelofibrosis.
- Cytogenetic and molecular abnormalities in chronic myelomonocytic Leukemia.
- Definition and management of ruxolitinib treatment failure in myelofibrosis.
- Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic Leukemia.
- Imetelstat therapy in refractory Anemia with ring sideroblasts with or without thrombocytosis.
Schools
University Of Athens School Of Health Sciences
Mayo Grad School MedMayo Fndn
St Joseph Hospital
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
Mayo School of Graduate Medical Education -
St Joseph Hospital -
University of Athens
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1518946987 | |
| NPPES Provider LastName | TEFFERI | |
| NPPES Provider FirstName | AYALEW | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 71.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1518946987 |
| Last Name Of The Provider | TEFFERI |
| First Name Of The Provider | AYALEW |
| View All |
Similar Doctors
|
|
Dr. Patrick B. Johnston, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Naseema Gangat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Prashant Kapoor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patricia T. Greipp, MD |
|
|
Dr. Sameer A. Parikh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tamana Walia, MD |
|
|
Dr. Aneel A. Ashrani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John A. Lust, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Heidi A. McKean, MD |
|
|
Dr. Robert J. Hoyer, MD |
|
|
Dr. Tait D. Shanafelt, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Luis F. Porrata, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rakhee R. Vaidya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Juliana Perez Botero, MD |
|
|
Dr. Alexis D. Leal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ben Y. Zhang, MD
This Doctor is OpenDoctor Recommended.
|